The Nature article provides an opportunity for me to expand upon repeatability and reproducibility, and why these dimensions of Provectus' work underscore my investment thesis.
Repeatability has long been there.
Reproducibility has been as well, but not as much, until now: the results of Moffitt's immunology-related work presented at SSO, and the results of work already done but not yet presented and the results of work to be done.
Publications don't necessarily lead to good products and businesses, or, by themselves, are [clearly] not predictors of good or great outcomes. Repeated and reproduced results generally do and are.